Ernexa Therapeutics Inc. Deferred Revenue Recognized
Ernexa Therapeutics Inc. (ERNA) reported Deferred Revenue Recognized of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-03-13
- Ernexa Therapeutics Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-09-30 was $200.00K, a 100.00% increase year-over-year.
- Ernexa Therapeutics Inc. contract with customer, liability, revenue recognized for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Ernexa Therapeutics Inc. contract with customer, liability, revenue recognized for fiscal 2024 was $600.00K, a 500.00% increase from fiscal 2023.
- Ernexa Therapeutics Inc. contract with customer, liability, revenue recognized for fiscal 2023 was $100.00K.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 9 month as first filed | Contract with Customer, Liability, Revenue Recognized 12 month | Contract with Customer, Liability, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-13 | |||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | |||||
| 2024-12-31 | $600.00K 10-K · filed 2026-03-13 | $300.00K 10-K · filed 2025-03-12 | ||||
| 2024-09-30 | $200.00K 10-Q · filed 2025-11-07 | $600.00K 10-Q · filed 2025-11-07 | $200.00K 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-13 | $100.00K 10-Q · filed 2025-08-13 | ||||
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-07 | |||||
| 2023-12-31 | $100.00K 10-K · filed 2025-03-12 | |||||
| 2023-09-30 | $100.00K 10-Q · filed 2024-11-12 | $100.00K 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | |||||
| 2020-09-30 | -$540.00K 10-Q · filed 2020-11-13 | |||||
| 2020-06-30 | -$266.00K 10-Q · filed 2020-08-07 | |||||
| 2020-03-31 | -$256.00K 10-Q · filed 2020-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |